Westway Health is developing a number of products based on their innovative technologies. Our lead product in development is PanaMastTM LC for the treatment of bovine mastitis in lactating cows. This is entering the late stage of development prior to submission of a regulatory dossier for approval by the relevant regulatory authorities. This aims to become the worlds first and only zero withdrawal therapy, allowing farmers to sell milk both during and immediately following treatment. Current antibiotic treatments require a withdrawal period of up to 9.5 days. This, therefore, has the potential to revolutionise the treatment of mastitis in this large, growing global market.